Treatment Satisfaction With Ra-223 Among Japanese Castration Resistant Prostate Cancer (CRPC) Patients

Trial Profile

Treatment Satisfaction With Ra-223 Among Japanese Castration Resistant Prostate Cancer (CRPC) Patients

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 25 Oct 2017 New trial record
    • 24 Oct 2017 Planned initiation date changed from 20 Oct 2017 to 15 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top